Valuation : Alumis Inc.

Market Cap 1.44B 1.24B 1.16B 1.06B 1.99B 136B 1.99B 13.75B 5.33B 69.6B 5.4B 5.28B 224B P/E 2026 *
-3.4x
P/E 2027 * -3.93x
Enterprise Value 721M 620M 584M 533M 997M 68.05B 1B 6.9B 2.68B 34.91B 2.71B 2.65B 112B EV / Sales 2026 *
115x
EV / Sales 2027 * 37.9x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Alumis Inc.

1 day-2.29%
1 week-50.40%
Current month-49.11%
1 month-59.07%
3 months-41.76%
6 months-59.84%
Current year+13.73%
1 week 8.75
Extreme 8.75
22.54
1 month 8.75
Extreme 8.75
28.17
Current year 7.85
Extreme 7.85
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Director/Board Member 55 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Sell

Chief Technology Officer

-2,447 0.0020%
8/3/26 Sell

Executive/Senior Manager

-2,692 0.0022%
8/3/26 Sell

General Counsel

-1,364 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-50.40%+146.12% - 1.44B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.47%-4.81%+53.04%+177.58% 28.05B
Weighted average by Cap. -1.52%-0.08%+38.93%+137.35%

Financials

2026 *2027 *
Net sales 6.26M 5.39M 5.07M 4.63M 8.66M 591M 8.69M 59.9M 23.24M 303M 23.51M 23M 977M 24.33M 20.94M 19.7M 18M 33.67M 2.3B 33.76M 233M 90.34M 1.18B 91.38M 89.39M 3.8B
Net income -427M -368M -346M -316M -591M -40.34B -593M -4.09B -1.59B -20.7B -1.6B -1.57B -66.68B -409M -352M -331M -302M -565M -38.58B -567M -3.91B -1.52B -19.8B -1.53B -1.5B -63.77B
Net Debt -716M -616M -580M -530M -991M -67.6B -993M -6.85B -2.66B -34.68B -2.69B -2.63B -112B -514M -442M -416M -380M -711M -48.52B -713M -4.92B -1.91B -24.89B -1.93B -1.89B -80.2B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
26-09-04 US$11.10 -2.29% 3,078,140
26-09-03 US$11.36 +9.76% 7,550,083
26-09-02 US$10.35 +9.29% 10,382,833
26-09-01 US$9.470 -56.58% 28,399,012
26-08-31 US$21.81 -2.55% 1,373,434
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
11.10USD
Average target price
32.12USD
Spread / Average Target
+189.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock